• Vol. 37 No. 1, 72–74
  • 15 January 2008

Intraocular Avastin (Bevacizumab) for Neovascularisation of the Iris and Neovascular Glaucoma

187



187 Views
28 Downloads

Download PDF

ABSTRACT

Introduction: The aim of this study was to determine the effectiveness of intraocular injections of bevacizumab for neovascularisation of the iris and neovascular glaucoma.

Clinical Picture: Three patients with neovascularisation of the iris due to various causes were recruited.

Treatment: Patients were treated with intraocular bevacizumab.

Outcome: Neovascularisation of the iris was noted to have completely regressed as early as 3 days after the injection and in all the patients (100%) within 8 days after injection. They were followed up for at least 1 month with no clinical evidence of recurrence. Visual acuity remained stable or improved, and the intraocular pressure was controlled in all the 3 patients’ eyes. Vitreous haemorrhage also cleared. No signs of inflammation or complications were observed.

Conclusion: Intraocular injection of bevacizumab is effective and safe for patients with neovascularisation of the iris and neovascular glaucoma with or without vitreous haemorrhage.


Neovascularisation of the iris is associated with many ischaemia retinal disorders and elevated levels of the vascular endothelial growth factor is found in patients with neovascular glaucoma. Inhibition of the vascular endothelial growth factor has been shown to prevent retinal ischaemia-associated neovascularisation of the iris.

This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.